Defeating malaria together

Interactive R&D portfolio

MMV’s portfolio focuses on delivering efficacious medicines that are affordable, accessible and appropriate for use in malaria endemic areas. Specifically, the goal is to develop products that will provide: efficacy against drug-resistant strains of Plasmodium falciparum, potential for intermittent treatments (infants and pregnancy), safety in small children (less than 6 months old), safety in pregnancy, efficacy against Plasmodium vivax (including radical cure), efficacy against severe malaria, and transmission-blocking treatment.

For more information about the global malaria portfolio, read the article: Malaria medicines: a glass half full? 

Detailed information is available below (click on the boxes) for translational, development and access projects. This interactive portfolio is updated twice a year, at 1Q and 3Q. 


Legend

* Pending review or approval by WHO prequalification, or by regulatory bodies who a ICH members or observers


 Brought into portfolio after approval. Collaboration with DNDi.

Brand names

1 Coartem® Dispersible
2 Artesun® 
3 Eurartesim®
4 Pyramax®
5 CoarsucamTM, ASAQ Winthrop® 
6 SPAQ-COTM

Target Product Profiles - represented by coloured bar(s) under the project box

____  3-day cure/artemisinin-based combination therapies

____  single-dose cure or multiple exposure cure in drug resistant malaria

____  Severe malaria

____  Chemoprevention

____  Relapse prevention

Target Candidate Profiles- represented by icons


 Asexual blood stage activity (TCP1,2)


 Relapse prevention (TCP3a)


 Transmission reduction (gametocytocidal or sporontocidal) (TCP3b)


 Chemoprevention (TCP4)